BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAWS
AbstractBisphosphonates are used widely for a variety of bone conditions, most notably intravenousbisphosphonate in the treatment of metastatic bone lesions and multiple myeloma and oralbisphosphonates for osteoporosis. Recently, a peculiar form of osteonecrosis limited to the jaws hasbeen discovered especially with the use of intravenous bisphosphonates. We review briefly themechanism of action of these drugs, the clinical features and staging of the disease, preventionstrategies and management options.Keyword: BRONJ, Multiple myeloma, Hyperbaric oxygen
Sato M, Grasser W, Endo N, Akins R, Simmons H,
Thompson DD, et al. Bisphosphonates action. Alendronate
localization in rat bone and effects on osteoclast
ultrastructure. J Clin Invest 1991;88:2095‒105.
Russell RG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM,
Dietz AA, et al. Inorganic pyrophosphate in plasma, urine,
and synovial fluid of patients with pyrophosphate
arthropathy (chondrocalcinosis or pseudogut). Lancet
Rodan GA, Reszka AA. Bisphosphonate mechanism of
action. Curr Mol Med 2002;2:571‒7.
Rogers MJ, Gordon S, Benford HL, et al. Cellular and
molecular mechanisms of action of bisphosphonates. Cancer
American College of Obstetricians and Gynecologists,
Women’s Health Care Physicians. ACOG practice bulletin.
Clinical management guidelines for obstetriciansgynecologists. Obstet Gynecol 2004;103:203‒16.
Hortobagyi GN, Theriualt RL, Porter I, et al. Efficacy of
pamidronate in reducing skeletal complications in patients
with breast cancer and lytic bone metastasis. N Engl J Med
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA,
Bordoni R, George S, et al. Efficacy of pamidronate in
reducing skeletal events in patients with advanced multiple
myeloma. N Engl J Med 1996;334:448‒93.
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A,
Yee GC, et al. American society of clinical oncology clinical
practice guidelines: the role of bisphosphonates in multiple
myeloma. J Clin Oncol 2002;20:3719‒36.
Conte P, Guarneri V. Safety of intravenous and oral
bisphosphonates and compliance with dosing regimens.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa)
induced avascular necrosis of the jaws: a growing epidemic.
J Oral Maxillofac Surg 2003;61:1115‒7.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S.
Osteonecrosis of the jaws associated with the use of
bisphosphonates: a review of 63 cases. J Oral Maxillofac
Robinson NA, Yeo JF. Bisphosphonates: a word of caution.
Ann Acad Med Singapore 2004;33:48–9.
Migliorati CA, Schubert MM, Peterson DE, Seneda LM.
Bisphosphonates-associated osteonecrosis of mandibular and
maxillary bone: an emerging oral complication of supportive
cancer therapy. Cancer 2005;104:83‒93.
Marx RE, Sawatari Y, Fortin M, Broumand V.
Bisphosphonate-induced exposed bone (Osteonecrosis/
osteopetrosis) of the jaws: Risk factors, recognition,
prevention and treatment. J Oral Maxillofac Surg
Advisory Task Force on Bisphosphonate-Related
Ostenonecrosis of the Jaws, American Association of Oral
and Maxillofacial Surgeons. American association of oral
and maxillofacial surgeons position paper on
bisphosphonate-related osteonecrosis of the jaws. J Oral
Maxillofac Surg 2007;65:369‒76.
Marx RE. Osteoradionecrosis: A new concept of its
pathophysiology. J Oral Maxillofac Surg 1983;41:351.
Marx RE, Johnson RP. Studies in the radiobiology of
osteoradionecrosis and their clinical significance. Oral Surg
Oral Med Oral Pathol 1987;64:379.
Marx RE, Cillo JE, Ulloa JJ. Oral Bisphosphonate-Induced
Osteonecrosis: Risk Factors, Prediction of Risk Using Serum
CTX Testing, Prevention, and Treatment. J Oral Maxillofac
Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related
osteonecrosis of the jaw: Background and guidelines for
diagnosis, staging and management. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod 2006;102:433‒41.
Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH,
Boneta O, Moon RE, et al. Hyperbaric Oxygen Treatment
and Bisphosphonate-Induced Osteonecrosis of the Jaw: A
Case Series. J Oral Maxillofac Surg 2007;65:1321‒7.
Curi MM, Cossolin GS, Koga DH, Araújo SR, Feher O, dos
Santos MO, et al. Treatment of avascular osteonecrosis of
the mandible in cancer patients with a history of
bisphosphonate therapy by combining bone resection and
autologous platelet-rich plasma: Report of 3 cases. J Oral
Maxillofac Surg 2007;65:349‒55.
Engroff SL, Kim DD. Treating bisphosphonate osteonecrosis
of the jaws: Is there a role for resection and vascularized
reconstruction? J Oral Maxillofac Surg 2007;65:2374‒85.
Harper RP, Fung E. Resolution of bisphosphonate-associated
osteonecrosis of the mandible: possible application for
intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J
Oral Maxillofac Surg 2007;65:573‒80.